Rauan Kaiyrzhanov,Aboulfazl Rad,Sheng-Jia Lin,Aida Bertoli-Avella,Wouter W Kallemeijn,Annie Godwin,Maha S Zaki,Kevin Huang,Tracy Lau,Cassidy Petree,Stephanie Efthymiou,Ehsan Ghayoor Karimiani,Maja Hempel,Elizabeth A Normand,Sabine Rudnik-Schöneborn,Ulrich A Schatz,Marc P Baggelaar,Muhammad Ilyas,Tipu Sultan,Javeria Raza Alvi,Manizha Ganieva,Ben Fowler,Ruxandra Aanicai,Gulsen Akay Tayfun,Abdulaziz Al Saman,Abdulrahman Alswaid,Nafise Amiri,Nilufar Asilova,Vorasuk Shotelersuk,Patra Yeetong,Matloob Azam,Meisam Babaei,Gholamreza Bahrami Monajemi,Pouria Mohammadi,Saeed Samie,Selina Husna Banu,Jorge Pinto Basto,Fanny Kortüm,Mislen Bauer,Peter Bauer,Christian Beetz,Masoud Garshasbi,Awatif Hameed Issa,Wafaa Eyaid,Hind Ahmed,Narges Hashemi,Kazem Hassanpour,Isabella Herman,Sherozjon Ibrohimov,Ban A Abdul-Majeed,Maria Imdad,Maksudjon Isrofilov,Qassem Kaiyal,Suliman Khan,Brian Kirmse,Janet Koster,Charles Marques Lourenço,Tadahiro Mitani,Oana Moldovan,David Murphy,Maryam Najafi,Davut Pehlivan,Maria Eugenia Rocha,Vincenzo Salpietro,Miriam Schmidts,Adel Shalata,Mohammad Mahroum,Jawabreh Kassem Talbeya,Robert W Taylor,Dayana Vazquez,Annalisa Vetro,Hans R Waterham,Mashaya Zaman,Tina A Schrader,Wendy K Chung,Renzo Guerrini,James R Lupski,Joseph Gleeson,Mohnish Suri,Yalda Jamshidi,Kailash P Bhatia,Barbara Vona,Michael Schrader,Mariasavina Severino,Matthew Guille,Edward W Tate,Gaurav K Varshney,Henry Houlden,Reza Maroofian

Abstract:The acyl-CoA-binding domain-containing protein 6 (ACBD6) is ubiquitously expressed, plays a role in the acylation of lipids and proteins and regulates the N-myristoylation of proteins via N-myristoyltransferase enzymes (NMTs). However, its precise function in cells is still unclear, as is the consequence of ACBD6 defects on human pathophysiology. Using exome sequencing and extensive international data sharing efforts, we identified 45 affected individuals from 28 unrelated families (consanguinity 93%) with bi-allelic pathogenic, predominantly loss-of-function (18/20) variants in ACBD6. We generated zebrafish and Xenopus tropicalis acbd6 knockouts by CRISPR/Cas9 and characterized the role of ACBD6 on protein N-myristoylation with myristic acid alkyne (YnMyr) chemical proteomics in the model organisms and human cells, with the latter also being subjected further to ACBD6 peroxisomal localization studies. The affected individuals (23 males and 22 females), aged 1-50 years, typically present with a complex and progressive disease involving moderate-to-severe global developmental delay/intellectual disability (100%) with significant expressive language impairment (98%), movement disorders (97%), facial dysmorphism (95%) and mild cerebellar ataxia (85%) associated with gait impairment (94%), limb spasticity/hypertonia (76%), oculomotor (71%) and behavioural abnormalities (65%), overweight (59%), microcephaly (39%) and epilepsy (33%). The most conspicuous and common movement disorder was dystonia (94%), frequently leading to early-onset progressive postural deformities (97%), limb dystonia (55%) and cervical dystonia (31%). A jerky tremor in the upper limbs (63%), a mild head tremor (59%), parkinsonism/hypokinesia developing with advancing age (32%) and simple motor and vocal tics were among other frequent movement disorders. Midline brain malformations including corpus callosum abnormalities (70%), hypoplasia/agenesis of the anterior commissure (66%), short midbrain and small inferior cerebellar vermis (38% each) as well as hypertrophy of the clava (24%) were common neuroimaging findings. Acbd6-deficient zebrafish and Xenopus models effectively recapitulated many clinical phenotypes reported in patients including movement disorders, progressive neuromotor impairment, seizures, microcephaly, craniofacial dysmorphism and midbrain defects accompanied by developmental delay with increased mortality over time. Unlike ACBD5, ACBD6 did not show a peroxisomal localization and ACBD6-deficiency was not associated with altered peroxisomal parameters in patient fibroblasts. Significant differences in YnMyr-labelling were observed for 68 co- and 18 post-translationally N-myristoylated proteins in patient-derived fibroblasts. N-myristoylation was similarly affected in acbd6-deficient zebrafish and X. tropicalis models, including Fus, Marcks and Chchd-related proteins implicated in neurological diseases. The present study provides evidence that bi-allelic pathogenic variants in ACBD6 lead to a distinct neurodevelopmental syndrome accompanied by complex and progressive cognitive and movement disorders.

Biallelic variation in the choline and ethanolamine transporter FLVCR1 underlies a severe developmental disorder spectrum

Biallelic variation in the choline and ethanolamine transporter FLVCR1 underlies a pleiotropic disease spectrum from adult neurodegeneration to severe developmental disorders

Biallelic variation in the choline and ethanolamine transporter underlies a pleiotropic disease spectrum from adult neurodegeneration to severe developmental disorders

Biallelic Mutations in the Ferredoxin Reductase Gene Cause Novel Mitochondriopathy with Optic Atrophy

Resolution of SLC6A1 variable expressivity in a multi-generational family using deep clinical phenotyping and Drosophila models

Brain monoamine vesicular transport disease caused by homozygous SLC18A2 variants: A study in 42 affected individuals

Biallelic CRELD1 variants cause a multisystem syndrome, including neurodevelopmental phenotypes, cardiac dysrhythmias, and frequent infections

Mono and biallelic variants in cause severe neurodevelopmental disorders

Biallelic loss-of-function variants of ZFTRAF1 cause neurodevelopmental disorder with microcephaly and hypotonia

Further delineation of the phenotypic and metabolomic profile of ALDH1L2‐related neurodevelopmental disorder

Broadening the phenotypic and molecular spectrum of FINCA syndrome: Biallelic NHLRC2 variants in 15 novel individuals

Bi-allelic ACBD6 variants lead to a neurodevelopmental syndrome with progressive and complex movement disorders

Biallelic pathogenic variants in TRMT1 disrupt tRNA modification and induce a syndromic neurodevelopmental disorder

Clinical and genetic delineation of autosomal recessive and dominant ACTL6B-related developmental brain disorders

Biallelic variants in OGDH encoding oxoglutarate dehydrogenase lead to a neurodevelopmental disorder characterized by global developmental delay, movement disorder, and metabolic abnormalities

The clinical and molecular spectrum of the KDM6B-related neurodevelopmental disorder

Novel syndromic neurodevelopmental disorder caused by de novo deletion of CHASERR, a long noncoding RNA

Biallelic loss-of-function variants in CACHD1 cause a novel neurodevelopmental syndrome with facial dysmorphism and multisystem congenital abnormalities

Haploinsufficiency underlies the neurodevelopmental consequences of SLC6A1 variants

Biallelic mutations in neurofascin cause neurodevelopmental impairment and peripheral demyelination

Clinical and genetic characterization of patients segregating variants in KPTN, MINPP1, NGLY1, AP4B1, and SON underlying neurodevelopmental disorders: Genetic and phenotypic expansion